Regentatlantic Capital LLC Buys 1,005 Shares of Celgene Co. (CELG)

Share on StockTwits

Regentatlantic Capital LLC raised its stake in shares of Celgene Co. (NASDAQ:CELG) by 3.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 34,449 shares of the biopharmaceutical company’s stock after purchasing an additional 1,005 shares during the period. Regentatlantic Capital LLC’s holdings in Celgene were worth $3,083,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Edgewood Management LLC boosted its stake in shares of Celgene by 16.2% in the second quarter. Edgewood Management LLC now owns 13,924,544 shares of the biopharmaceutical company’s stock worth $1,105,887,000 after acquiring an additional 1,943,607 shares during the period. FMR LLC boosted its stake in shares of Celgene by 14.8% in the second quarter. FMR LLC now owns 8,160,001 shares of the biopharmaceutical company’s stock worth $648,067,000 after acquiring an additional 1,051,528 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Celgene by 60.6% in the second quarter. Renaissance Technologies LLC now owns 4,129,438 shares of the biopharmaceutical company’s stock worth $327,960,000 after acquiring an additional 1,558,600 shares during the period. Swedbank boosted its stake in shares of Celgene by 25.0% in the second quarter. Swedbank now owns 3,881,075 shares of the biopharmaceutical company’s stock worth $308,235,000 after acquiring an additional 777,099 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Celgene by 11.3% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,648,481 shares of the biopharmaceutical company’s stock worth $210,342,000 after acquiring an additional 268,597 shares during the period. 72.98% of the stock is owned by institutional investors and hedge funds.

In other Celgene news, Director Ernest Mario sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $92.32, for a total transaction of $1,107,840.00. Following the sale, the director now directly owns 44,413 shares in the company, valued at $4,100,208.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John H. Weiland acquired 5,575 shares of the firm’s stock in a transaction on Tuesday, August 7th. The shares were bought at an average price of $89.73 per share, for a total transaction of $500,244.75. The disclosure for this purchase can be found here. Corporate insiders own 0.39% of the company’s stock.

Shares of Celgene stock opened at $71.60 on Thursday. Celgene Co. has a 12 month low of $70.09 and a 12 month high of $110.81. The company has a market cap of $50.58 billion, a P/E ratio of 10.47, a PEG ratio of 0.44 and a beta of 1.30. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.02 by $0.27. Celgene had a return on equity of 108.76% and a net margin of 19.64%. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.83 billion. Research analysts predict that Celgene Co. will post 7.56 earnings per share for the current year.

A number of equities analysts have recently weighed in on the company. BidaskClub lowered Celgene from a “buy” rating to a “hold” rating in a research note on Thursday, September 13th. Cantor Fitzgerald assumed coverage on Celgene in a research note on Monday, October 1st. They issued an “overweight” rating and a $100.00 price objective for the company. Mizuho set a $117.00 price objective on Celgene and gave the stock a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a research note on Thursday, October 11th. Finally, Morgan Stanley upped their price objective on Celgene from $90.00 to $91.00 and gave the stock an “equal weight” rating in a research note on Friday, July 13th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $117.91.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: Technical Analysis of Stocks and What It Means

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply